Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences (NASDAQ: SSKN) announces a favorable court order in its complaint against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group. The order, issued by the US District Court for Eastern Pennsylvania, enjoins LaserOptek and Pinnacle from marketing Pallas lasers with claims about CPT Codes 96920-96922 reimbursement and prohibits false statements about Pallas or STRATA lasers. The ruling follows STRATA's August 2024 complaint citing unfair competition. The company will continue pursuing claims for equitable and monetary relief, defending against what it describes as misleading practices regarding non-excimer laser reimbursement claims.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its upcoming third quarter 2024 financial results release on November 13, 2024, after market close. Management will host a conference call at 4:30 p.m. ET the same day, including a Q&A session. U.S. participants can dial 1-844-481-2523, while international callers should use 1-412-317-0552. A webcast replay will be available until May 13, 2025, and a telephonic replay until November 20, 2024, using access code 4851779.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced that its Japanese distributor, JMEC Co., , sponsored a seminar featuring two lectures on XTRAC® excimer devices at the 75th Annual Meeting of the Chubu Branch of the Japanese Dermatological Association in Nagoya, Japan on October 12, 2024. The seminar, chaired by Professor Kazutoshi Harada of Tokyo Medical University, included presentations by:
1. Dr. Nobuhiro Nouchi from Nouchi Dermatology Clinic, discussing successful treatment of vitiligo and alopecia areata using XTRAC® excimer laser.
2. Dr. Osamu Norisugi from Keyaki Dermatology Clinic, sharing his clinic's experience in treating psoriasis, vitiligo, and alopecia areata with XTRAC® excimer laser since 2020.
This event highlights the growing recognition and use of STRATA's XTRAC® technology in the Japanese dermatology market.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its participation in the 2024 Maxim Healthcare Virtual Summit. President and CEO Dr. Dolev Rafaeli will engage in a fireside chat with Maxim's Director of Research and Senior Healthcare Analyst Anthony Vendetti on Wednesday, October 16, 2024, at 11:30am ET.
The virtual conference runs from October 15 to 17, 2024. Investors can access the fireside chat via webcast at https://m-vest.com/events/healthcare-10152024. Additionally, Dr. Rafaeli and STRATA V.P. Finance John Gillings will be available for one-on-one meetings with registered conference investors.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic conditions, announces its participation in the iAccess Alpha - Buyside Best Ideas Fall Conference 2024. The virtual event is scheduled for September 24-25, 2024.
Key details:
- President and CEO Dr. Dolev Rafaeli will present a corporate overview on September 24, 2024, at 12:30 PM ET
- Presentation webcast available at: https://www.webcaster4.com/Webcast/Page/3064/51242
- Dr. Rafaeli and V.P. Finance John Gillings will be available for one-on-one meetings with registered investors
- Investors can register and schedule meetings at: https://www.iaccessalpha.com/signup
This presentation offers an opportunity for investors to gain insights into STRATA's innovative products and market strategy in the dermatology sector.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced its participation in the Lake Street Capital Markets 8th Annual Best Ideas Growth Conference. The event is scheduled for September 12, 2024, at the Yale Club in Midtown Manhattan, New York City.
Dr. Dolev Rafaeli, President and CEO of STRATA, will represent the company at the conference. STRATA will be hosting one-on-one investor meetings throughout the event, providing an opportunity for investors to engage directly with the company's leadership. Interested parties can schedule meetings through their Lake Street representatives.
This participation underscores STRATA's commitment to investor relations and its ongoing efforts to showcase its innovative products in the dermatologic field to potential investors and industry professionals.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel.
Key points:
- President and CEO Dr. Dolev Rafaeli will present a corporate overview
- Presentation will be available on-demand starting September 9, 2024, at 7:00 am ET
- Investors can register for the conference at https://hcwevents.com/annualconference/
- Dr. Rafaeli and V.P. Finance John Gillings will be available for one-on-one meetings with registered investors
STRATA Skin Sciences (NASDAQ: SSKN) has filed a complaint against LaserOptek, Monarch Laser Services (MLS), and The Pinnacle Health Group for unfair competition and false advertising regarding the marketing and sales of Pallas laser devices. The lawsuit, filed in the U.S. District Court for the Eastern District of Pennsylvania, alleges that the defendants:
- Misrepresented the reimbursement eligibility of Pallas lasers for psoriasis treatments
- Made false claims about the equivalence and superiority of Pallas lasers to STRATA's XTRAC® devices
- Misused FDA clearance to make misleading statements
- Caused harm to public interest through fraudulent reimbursement practices
STRATA seeks injunctive relief, damages, and legal cost reimbursement to protect its 4,000 partners and patients using their proven excimer devices for dermatology treatments.
STRATA Skin Sciences (NASDAQ: SSKN) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Revenue increased 2% YOY to $8.4 million
- Gross profit margin improved to 58.5% from 52.3% last year
- Operating expenses decreased 14% YOY to $5.4 million
- Net loss narrowed to $0.1 million ($0.03 per share) from $3.1 million ($0.90 per share) in Q2 2023
- Cash balance increased to $6.8 million
- Domestic XTRAC installed base decreased to 882 devices as the company optimizes its asset base
- TheraClear X installed base grew to 117 devices
- Completed a $2.1 million financing in July 2024
The company is focusing on DTC marketing and optimizing its device installed base to drive growth and profitability.
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced its plans to report second quarter 2024 financial results on August 14, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Interested parties can join the call by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international). A live webcast will also be available. A telephonic replay will be accessible until August 21, 2024, and a webcast replay will be available until February 14, 2025.